We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
Read MoreHide Full Article
Key Takeaways
BSX's Q3 gross and operating margins improved on a favorable mix from EP and WATCHMAN growth.
BSX's WATCHMAN sales jumped 35% with rising U.S. concomitant adoption and broader patient penetration.
BSX's EP sales surged 63% as FARAPULSE adoption accelerated, supported by OPAL HDx system uptake.
Boston Scientific (BSX - Free Report) posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly driven by a favorable product mix, supported by strong growth in electrophysiology (EP) and WATCHMAN units. However, tariffs restricted the full extent of that growth. The adjusted operating margin climbed 80 bps year over year to 28%, driven by solid drop-through on the company’s top-line performance.
Breaking down the components, WATCHMAN’s third-quarter sales rose 35%, with total patients treated now exceeding 600,000. The momentum was driven by the accelerated concomitant adoption in the United States and ongoing penetration within the 5 million patients, supported by strong clinical evidence and awareness among patients and physicians. Boston Scientific continues to project approximately 25% of the U.S. WATCHMAN procedures to be done concomitantly by the end of 2025.
Meanwhile, Boston Scientific’s continued share gains in the overall EP market are impressive. EP sales surged 63% year over year, aided by the continued growth of the Farapulse Pulsed Field Ablation (“PFA”) System. In the United States, double-digit growth in FARAPULSE was due to the accelerated adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now using the integrated FARAWAVE NAV and OPAL device. Boston Scientific expects global PFA penetration to keep expanding and reach about 50% by the end of 2025.
Based on third-quarter performance, Boston Scientific expects the full-year adjusted gross margin to come in slightly above the 2024 levels, accounting for an estimated $100 million tariff headwind. Management also continues to project adjusted operating margin expansion of approximately 100 bps at the high end of the prior 75-100 bps range.
Latest Updates From BSX’s Peers
Abbott (ABT - Free Report) has entered into a definitive agreement to acquire Exact Sciences, the developer of the Cologuard non-invasive colorectal cancer screening test. The acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
GE Healthcare (GEHC - Free Report) has entered into an agreement to acquire Intelerad, a medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition reflects the company’s continued commitment to cloud-enabled and AI-powered solutions across care settings and advances its goal to triple its offerings of cloud-enabled products by 2028.
BSX Price Performance, Valuation and Estimates
Year to date, Boston Scientific shares have risen 9.8% compared with the industry’s 3.4% growth.
Image Source: Zacks Investment Research
In terms of valuation, Boston Scientific shares trade at a forward 12-month Price-to-Sales (P/S) ratio of 6.59, lower than their median but above their industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend, as you can see.
Image: Bigstock
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
Key Takeaways
Boston Scientific (BSX - Free Report) posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly driven by a favorable product mix, supported by strong growth in electrophysiology (EP) and WATCHMAN units. However, tariffs restricted the full extent of that growth. The adjusted operating margin climbed 80 bps year over year to 28%, driven by solid drop-through on the company’s top-line performance.
Breaking down the components, WATCHMAN’s third-quarter sales rose 35%, with total patients treated now exceeding 600,000. The momentum was driven by the accelerated concomitant adoption in the United States and ongoing penetration within the 5 million patients, supported by strong clinical evidence and awareness among patients and physicians. Boston Scientific continues to project approximately 25% of the U.S. WATCHMAN procedures to be done concomitantly by the end of 2025.
Meanwhile, Boston Scientific’s continued share gains in the overall EP market are impressive. EP sales surged 63% year over year, aided by the continued growth of the Farapulse Pulsed Field Ablation (“PFA”) System. In the United States, double-digit growth in FARAPULSE was due to the accelerated adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now using the integrated FARAWAVE NAV and OPAL device. Boston Scientific expects global PFA penetration to keep expanding and reach about 50% by the end of 2025.
Based on third-quarter performance, Boston Scientific expects the full-year adjusted gross margin to come in slightly above the 2024 levels, accounting for an estimated $100 million tariff headwind. Management also continues to project adjusted operating margin expansion of approximately 100 bps at the high end of the prior 75-100 bps range.
Latest Updates From BSX’s Peers
Abbott (ABT - Free Report) has entered into a definitive agreement to acquire Exact Sciences, the developer of the Cologuard non-invasive colorectal cancer screening test. The acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
GE Healthcare (GEHC - Free Report) has entered into an agreement to acquire Intelerad, a medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition reflects the company’s continued commitment to cloud-enabled and AI-powered solutions across care settings and advances its goal to triple its offerings of cloud-enabled products by 2028.
BSX Price Performance, Valuation and Estimates
Year to date, Boston Scientific shares have risen 9.8% compared with the industry’s 3.4% growth.
Image Source: Zacks Investment Research
In terms of valuation, Boston Scientific shares trade at a forward 12-month Price-to-Sales (P/S) ratio of 6.59, lower than their median but above their industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend, as you can see.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.